<DOC>
	<DOCNO>NCT02018536</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability , pharmacokinetic ( body medication ) GSK2336805 alone co-administration TMC435 healthy Japanese participant .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability Pharmacokinetics GSK2336805 Alone With Co-administration TMC435 Healthy Japanese Participants .</brief_title>
	<detailed_description>This study consist 2 part ( Part 1 2 ) sequentially conduct 2 separate panel 24 healthy adult Japanese participant , single center . Part 1 double-blind ( neither physician participant know treatment participant receives ) , placebo-controlled ( placebo compare study medication test whether study medication real effect clinical study ) , randomize ( study medication assign chance ) , single ascend dose study investigate safety , tolerability , pharmacokinetics GSK2336805 participant . It consist screen phase , treatment phase , follow-up phase . The maximum study duration participant approximately 5 week ( include screen follow-up phase ) . 24 participant equally divide 3 cohort 8 participant cohort . In cohort , participant randomly assign receive either single oral dose GSK2336805 ( 6 participant ) placebo ( 2 participant ) . Part 2 open-label ( people know identity intervention ) , randomize , 4-way crossover study ( method use switch patient one treatment arm another clinical study ) investigate potential pharmacokinetic drug-drug interaction TMC435 GSK2336805 steady-state , evaluate short-term safety tolerability TMC435 GSK2336805 co-administered participant . It consist screen phase , treatment phase ( 4 treatment session [ Treatment A , B , C , D ] ) , follow-up phase . The maximum study duration participant approximately 12 week ( include screen follow-up phase ) . During 4 treatment session , 24 participant receive Treatment A , B , C D consecutively different sequence washout period least 7 day consecutive treatment session individual participant . Safety evaluate assess adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination , alcohol breath test , specific toxicity .</detailed_description>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Healthy Japanese participant basis medical history , physical examination , vital sign , triplicate 12lead electrocardiogram , clinical laboratory test perform screen Must sign Informed Consent Form ( ICF ) indicate understand purpose procedure require study Must willing adhere prohibition restriction specify protocol Women must nonchildbearing potential ( postmenopausal least 2 year surgically sterile ) Women , except postmenopausal woman , negative serum bhuman chorionic gonadotropin ( hCG ) pregnancy test screen History evidence current use alcohol , barbiturate , amphetamine , recreational narcotic drug use within past one year Participants hepatitis A , B , C infection human immunodeficiency virus type 1 ( HIV1 ) HIV2 infection study screen Female participant breastfeed screen History liver renal impairment ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , psychiatric , neoplastic , metabolic disturbance Participants know allergy , hypersensitivity , intolerance GSK2336805 , TMC435 excipients drug product use</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>TMC435</keyword>
	<keyword>GSK2336805</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
</DOC>